PapiVax Biotech, Inc.

4:15 PM - 4:30 PM (PDT), Monday, June 13, 2022
PapiVax Biotech, Inc. is developing immunotherapies for human papillomavirus (HPV) infection and associated cancers (e.g., cervix & oropharynx). We have 2 heterologous prime-boost therapeutic vaccines: (1) PVX2 (DNA prime/fusion protein boost) treats persistent HPV16 cervical infection with LSIL/CIN1/ASCUS/ASCH in an ongoing phase II trial (NCT03911076) in US with promising first results; and (2) PVX7 (DNA prime/recombinant vaccinia boost), combined with an immune checkpoint inhibitor, treats HPV16/18+ advanced cervical cancer (phase II IND approved by US FDA). PVX2 leads its field without competition. The patented immunotherapies are designed for safety as well as optimal expression/trafficking/processing of viral proteins for the most potent antitumor immune responses. They are innovative, adjuvant-free, simple to administer (IM), well tolerated in tested subjects, easy to store, highly stable and can be mass produced quickly at a relatively low cost. (ref: PMID: 33468698, 26918115)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Taiwan
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
PVX2, PVX7
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2